Delcath (DCTH $3.99 +0.34) is trading up 10% after the company reported top-line results from the hepatobiliary cohort of the Phase II clinical trial of the Delcath chemosaturation system with melphalan in the treatment of patients with unresectable liver cancer.
There were nine patients with tumors of hepatobiliary origin: five hepatocellular carcinomas and four cholangiocarcinomas. Both groups had positive efficacy signals.
The responses were especially encouraging in the HCC cohort and consisted of confirmed partial response or durable stable disease. The safety profile of the chemosaturation system was consistent with that previously reported for the Company's Phase 3 melanoma trial.






